South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down By Ty Roush, Forbes Staff. Ty Roush is a breaking news reporter based in New York City.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

Eli Lilly (NYSE:LLY) is set to release its earnings on Thursday, August 7, 2025. In the past, Eli Lilly’s stock has displayed a pattern of negative one-day returns following earnings announcements.

Eli Lilly stock hasn't been performing this badly since the Great Recession Prior to Thursday's sell-off, the stock was on track for its worst year since 2016.

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength.

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the drugmaker tumbling.

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on genetics and financial implications.

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall Street.

Eli Lilly (LLY 2.95%) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index.